ASH 2022 | Exploring novel treatment strategies for Ph-like ALL
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, briefly discusses the challenges of treating patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), and treatment strategies of interest, including tyrosine kinase inhibitors (TKIs) and immunotherapeutic agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.
